Jam

Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.

PetroFrontier Corp. (TSXV: PFC) announces further delays in filing financial statements. Annual filings are now expected by June 26, 2025 and Q1 filings by July 10, 2025, impacting CEO/CFO trading and an existing cease trade order. The company cites data delays from its limited partnership investment. While providing biweekly updates, PetroFrontier, focused on Alberta heavy oil plays, faces exchange listing risks related to these delays.

Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.

A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.

Tempus AI launched its Fuses program to create an AI-powered diagnostic platform for precision medicine. Leveraging its vast, multimodal dataset, the initiative will build models to improve diagnostics, prognostics, and predictions. Fuses aims to translate data insights into clinically validated tests for personalized patient care, including identifying those unlikely to respond to current therapies. The program seeks to transform diagnostics and help match patients with the most effective treatments.

Genentech announced positive overall survival data from the Phase III INAVO120 study, showing that the Itovebi regimen reduced death risk by over 30% in advanced breast cancer patients with PIK3CA mutations. Compared to palbociclib and fulvestrant alone, this Itovebi combination with palbociclib and fulvestrant significantly improved overall survival. The findings will be presented at the 2025 ASCO meeting.

Destination XL Group (DXLG) opened a new DXL store in Boca Raton, Florida, its fifth new store this fiscal year. Catering to Big + Tall menswear, the store offers exclusive designs and various brands. DXL utilizes FiTMAP^SM Sizing Technology for personalized recommendations. This expansion aims to provide a streamlined shopping experience and empower customers to express their personal style through well-fitting apparel.

Gold Reserve Ltd. announced a deadline extension in the Citgo Petroleum sale linked to Venezuela. The U.S. District Court granted the Venezuelan parties more time to submit bids for PDVH, Citgo’s holding company, with a new “Topping Period” deadline of June 18, 2025. Key dates for legal proceedings were also outlined, including a final recommendation by June 27, 2025, and a sale hearing on July 22, 2025. Gold Reserve anticipates bidding but acknowledges the deal faces significant risks, including potential regulatory challenges.

St. Augustine Gold and Copper (SAU.T) has restructured its KingKing Copper-Gold Project ownership in the Philippines, consolidating development rights. This involved a $9.12 million convertible note issued to its partner, Nadecor, allowing conversion into shares, acquiring all Kingking Milling Corporation shares and streamlining the project. This strategic move aims to facilitate project financing and capitalize on the high-potential project, considered a top priority by the Philippine government. The company also includes cautionary forward-looking statements about potential risks.

Avant Brands Inc. concluded its annual general meeting on May 30, 2025, with 16.19% of outstanding shares represented. Shareholders elected all six nominated directors, re-appointed Ernst & Young LLP as auditor, and approved several proposals, including the deferred share unit plan, its amendments, long-term incentive plan, its amendments, and the repricing of warrants and convertible debentures. Complete voting details reside on SEDAR+.